Pharmaceuticals, Biotechnology & Life Sciences

Explore how Cingulate Inc.’s board shrinkage and new chairman reshape its strategy, boosting efficiency and accelerating drug development for patients.

FDA approves Daiichi Sankyo’s Datroway as first‑line therapy for triple‑negative breast cancer, boosting the company’s oncology profile and investor confidence.

Quantum‑Si’s latest ownership shifts show no operational impact, while its chip‑powered protein sequencing tech keeps pushing proteomics toward new drug discovery breakthroughs.

Agios Pharmaceuticals drives cancer therapy forward by targeting glycolysis, fatty‑acid metabolism, and autophagy—revealing a biotech breakthrough poised to reshape precision medicine.

BriaCell Therapeutics pioneers breast cancer immunotherapy with its patented BriaVax vaccine, driving biotech innovation and patient hope—discover how the company is reshaping cancer treatment.

Explore Sangamo Therapeutics’ latest stock performance, market position, and focus on genetic therapies, and how its volatility reflects biotech trends.

Humanwell Healthcare Group Co Ltd’s Shanghai Stock Exchange performance, valuation, and global pharmaceutical strategy revealed – insights into its market value, P/E ratio, and growth prospects.

Newron Pharmaceuticals shares dip slightly in Zurich, reflecting modest market movements and a negative P/E of –23.2. The biopharma firm focuses on CNS therapies, including Parkinson’s and neuropathic pain treatments, while navigating high volatilit…

Firetrail exits PYC Therapeutics: what this means for the Aussie biotech stock’s future

Shenzhen Salubris Pharma: capitalizing on China’s new drug laws, a promising pipeline, and MedTech 50 rally, this undervalued stock offers upside potential.